# Silvia Mariel Ferrucci

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/silvia-mariel-ferrucci/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,734 |
| Field | Dermatology and Skin Diseases |
| h-index | 32 |
| i10-index | 99 |
| Last Known Institution | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico |
| OpenAlex ID | https://openalex.org/A5081303333 |
| ORCID iD | 0000-0002-6734-1366 |
| Works | 263 |

## Researcher papers

- [Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-lebrikizumab-in-combination-with-topical-corticosteroids/)
- [Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients](https://scholariq.org/papers/predictors-of-response-to-omalizumab-and-relapse-in-chronic-spontaneous/)
- [Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices.](https://scholariq.org/papers/staging-of-classic-kaposi-s-sarcoma-a-useful-tool-for-therapeutic-choices/)
- [Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria](https://scholariq.org/papers/co-occurrence-of-ige-and-igg-autoantibodies-in-patients-with-chronic-spontaneous/)
- [Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study](https://scholariq.org/papers/dupilumab-therapy-of-atopic-dermatitis-of-the-elderly-a-multicentre-real-life/)
- [Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis](https://scholariq.org/papers/real-life-experience-on-effectiveness-and-safety-of-dupilumab-in-adult-patients/)
- [The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria](https://scholariq.org/papers/the-global-impact-of-the-covid-19-pandemic-on-the-management-and-course-of/)
- [D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria](https://scholariq.org/papers/d-dimer-plasma-levels-parallel-the-clinical-response-to-omalizumab-in-patients/)
- [HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma](https://scholariq.org/papers/hhv8-a-subtype-is-associated-with-rapidly-evolving-classic-kaposi-s-sarcoma/)
- [Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis](https://scholariq.org/papers/urticarial-vasculitis-clinical-and-laboratory-findings-with-a-particular/)
- [One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis](https://scholariq.org/papers/one-year-insights-into-the-globostad-multinational-prospective-observational/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico](https://scholariq.org/institutions/fondazione-irccs-ca-granda-ospedale-maggiore-policlinico/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.